CELMoD Mechanism and Differentiation From IMiDs in Multiple Myeloma

Dr. Mikhael begins the scientific foundation by asking Dr. Richardson to define CELMoDs and explain how they engage the cereblon E3 ubiquitin ligase complex to promote targeted degradation of Ikaros and Aiolos, key transcription factors involved in myeloma-cell biology. Dr. Richardson contrasts CELMoDs with established immunomodulatory drugs (IMiDs), including lenalidomide and pomalidomide, emphasizing differences in molecular design and cereblon engagement. He describes how more pronounced engagement of the cereblon complex can result in deeper degradation of these substrates and discusses the potential relationship between this activity and antimyeloma effects, including activity observed in disease resistant to prior IMiD therapy. The discussion also touches on immune-mediated effects and the concept of on-target neutropenia associated with CELMoD activity. Together, the faculty establish the mechanistic rationale for considering CELMoDs as a next-generation class in multiple myeloma, while distinguishing their molecular properties from those of established IMiDs.